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Patient registries are organized systems of data collection for scientific, clinical or health strategy purposes.
Aims of our review were to document scientific literature based on data and information from cystic fibrosis (CF) registries; to understand
which clinical problems have been addressed and for which of these the studies concerned have correctly answered the questions raised (i.e. a
methodological critique) and to identify clinical issues in need of further investigation. The review included primary studies starting from a
formally constituted CF registry of at least national level, using data from the registry to evaluate research hypotheses.
This article is an overview of the research undertaken, focusing in detail on the issues of mortality and survival. The studies considered here
focused mainly or secondarily on survival in CF, the aim being to ascertain an improving trend, identify any prognostic factors and, in some cases,
attempt to provide a predictive model of survival.
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Patient registries are organized systems of data collection for
scientific, clinical or health strategy purposes. They are a valid
complement to controlled, randomized clinical trials for
assessing outcomes of actual medical practice; inclusion and
exclusion criteria are not restrictive, provided that diagnostic
procedures for placing patients in the registry are sound and
consistent.
Registries can serve a variety of purposes, including: determina-
tion of cost-efficiency, comparative efficacy and acceptability of a
treatment or diagnostic procedure; measurement and monitoring of
therapeutic safety and treatment-specific adverse events, including
comparative safety and efficacy evaluation; measurement or
improvement of the quality of healthcare; assessment of the natural
history and extent of a pathological disorder; determination of its
incidence and prevalence; examination of disease trends and
patterns over a period of time; surveillance; assessment of
healthcare services; identification of high-risk groups; documenta-
tion of available treatments; estimation of survival, etc.
Following a training course entitled “The Italian Cystic Fibrosis
Registry: a resource for teaching, awareness-raising and healthcare
organization” (organized in Verona by the Italian Cystic Fibrosis
Research Foundation, from January to December 2006), partici-
pants undertook a narrative review of scientific literature based on
the various cystic fibrosis (CF) patient registries.
The aims of the study were to document scientific literature
based on data and information from CF registries, to understand
which clinical problems have been addressed and for which of
these the studies concerned have correctly answered the
questions raised, and to identify clinical issues in need of
further investigation.
This article, the first of a series of three papers presenting an
overview of the research undertaken, focuses in detail on the
issues of mortality and survival.2. Methods
Starting from the premiss that not all scientific studies
including some sort of reference to registries would without
exception prove strictly relevant to our aims, the following
criterion was established for inclusion in our review: primary
studies starting from a formally constituted CF registry of at
least national level, using data from the registry to describe
aspects of the disease or to advance research hypotheses.
The review excluded studies based on unofficial registries
(cohort studies), local registries or non CF registries; studies
using registry data as a simple external control or for
recruitment to randomized clinical trials; reviews, commen-
taries, editorials and letters; articles with no more than a simple
bibliographic reference to registries; annual reports of registries;
replications of already published articles.A bibliographic search was carried out in Pubmed and
Embase, updated to 30/06/08, with the following strategy:
(“Cystic fibrosis”[MESH] AND (“Registry”[MESH]) OR
registr$)).
Two independent assessors (DS and GM) reviewed all the
abstracts of the articles found. Any cases of disagreement were
resolved through extensive discussion and negotiation of a
common position.
Contact persons for the registries mentioned in the studies
were interviewed by postal questionnaire and the following
items were collected (see Table 1): year of commencement of
the registry; number of patients as at 31/12/06 (total and living);
list of variables (a manual of definitions being provided where
applicable); territory covered; degree of completeness of data;
number of participating centres; composition of staff (steering
committee, organizational chart, number of staff/hours worked
per week); periodical reporting arrangements; number and list
of publications; name of questionnaire respondent; description
of quality control system; estimated cost of the registry (and
details of source of financing); and frequency of data collection.
Articles were subdivided into the following topics according
to the main items dealt with:
1. general epidemiology (disease incidence/prevalence, survi-
val, comparison of registries);
2. genetic issues (prevalence and distribution of the most
common CFTR mutations, genotype/phenotype correlation,
different ethnic groups and twins/siblings);
3. neonatal screening and its effects;
4. growth and nutrition;
5. microbiology;
6. pregnancy and fatherhood;
7. complications;
8. organ transplants;
9. other.
These topics were not mutually exclusive, so studies could
be classified in more than a single category.
A total of 115 studies were thus analysed, using a grid
developed by the participants attending the training course
(Table 2). The choice of an original method for evaluation of
literature was one of the aims of the training course.
3. Results
3.1. General results of data bank search
The search in the two main data banks (PubMed and
Embase) made it possible to identify 193 articles, 90 of which
met the inclusion criteria. The lists of publications provided by
the main registries completed the data retrieved in the
bibliographic search: 133 articles were pointed out, of which
50 had already been identified by the data bank search; of the
Table 1
Overview of information provided by Registries (end 2006).
Country
and name
USA-CFF
Patient
registry
USA-Epidemiologic
Study of CF
Canadian CF
Patients Data
Registry
Australian
CF
Data Registry
UK CF
Database
France-Observatoire
National de la
Mucoviscidose
Registro
Italiano FC
German CF Quality
Assessm. Proj.
Registre Belge de la
Mucoviscidose
(BMR-RBM)
Cystisk fibrose
register Danmark
European a
Registry
CF(ERCF)
Affiliation CF
Foundation
Genentech Canadian
CFF
CF
Australia
University
of Dundee
Vaincre
la Mucoviscidose
Istituto di
Biometria,
Milano
Centre for Quality
and Management
Health Care, Hannover
Federal Public
Service— Scientific
Inst. Public Health
CF0 Centre, Aarhus,
DK University
Hospital
Genentech
La Roche
Inaugural
year
1966 1994 1966 1988 1999–2006 1992 1988 1995 1998 2001 1995–2003
Patients 40,203 32,667 5571 n. a. 7046 4608 5064 7260 1140 460 13,684
N patients
living
22,987 n. a. 3453 2312 n. a. 4564 4099 6635 987 436 n. a.
Data
collection
Every visit Every visit Annual Variable Variable Annual Annual Annual Annual Annual Annual
Collection
tools
Software
on web
Software Software
on web
Software Software+
forms
Software+forms Software Software Software Software Software+
forms
Data quality
control
Feedback
to Centre
Automatic Statistical Automatic
system
Automatic
system
Automatic
feedback to centre
n. a. Automatic
system
Automatic
system
Local Feedback
to Centre
Data
protection
As required
by law
Coding Coding IT
safeguards
Coding Coding+IT
safeguards
As required
by law
n. a. As required
by law
Coding Coding+IT
safeguards
Anonymous
Frequency
of report
Annual None Annual Annual Annual Annual Annual Annual Annual Annual Annual
Publications 80 13 n. a. 0 15 8 4 5 2 0 6
Annual
Cost
$ 405,000 start-up
$ 2,500,000
running
$ 700,000
n. a. 165,000 € variable 250,000 € n. a. 120,000 € n.a.
(Covered by state)
4000 € n. a.
Funding Private
sponsors
Genentech Inc Public Private
sponsors
Public Mixed Mixed Private
foundation
Public Mixed Genentech
—La Roche
Contact
person(s)
H Quinton
O Brian
JS Wagener I McIntosh G Sims A Mehta G Bellis A Bossi M Stern M Thomas
H Jansen
HY Olese G Mastella
n. a.=not available.
a Europe: B, D, IR, F, NL, UK, A, DK, SW.
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Fig. 1. Search strategy and articles retrieved.
Table 2
A grid for data extraction and evaluation for each publication.
Reference
(year, title, authors, journal, registry)
Objectives
Clarity of objective explanation
Specificity of objectives
Description (incidence/prevalence of CF, mortality/survival,
genotype/phenotype correlation, efficacy and/or efficiency
of a treatment, effect of exposure, other)
Main focus
Survival, incidence, prevalence
Registry comparisons
Screening and its outcomes
Growth and nutrition
Genotype/phenotype correlation
Microbiology and related outcomes
Pregnancy and paternity
Complications (diabetes, nasal polyposis, ABPA, etc.)
Organ transplantations
Other (specify)
Study design
Type of study design
Observational: anecdotal, case report, cross-sectional,
before–after, time series, case-control, historic cohort,
prospective cohort, other.
Experimental: randomized controlled trial, other
Follow up (follow-up period, length of study, length of
follow-up, follow-up completeness)
Overall adequacy of the study
Comments
Participants
Gender, age, number of participants
Interventions
Diagnostic; therapeutic; exposure (natural, environmental etc).
Description and comparisons of interventions
Outcomes
Primary outcomes
Secondary outcomes
Statistical methods
Method description
Overall or specific adequacy of methods
Results
Main results (description)
Result interpretation and evaluation
Generalizability of results
Other comments
Relevance of the problem, usefulness of the study
232 R. Buzzetti et al. / Journal of Cystic Fibrosis 8 (2009) 229–237remaining 83, 25 fulfilled the inclusion criteria (see Fig. 1).
Those which could not be included were letters, editorials,
reviews, reports of recruitment from the registries for RCT, or
publications based on data from a limited number of centres
within the registry. The breakdown by registry and by topic is
presented in Table 3.
3.2. Results of survival studies
Most studies based on data from national CF registries were
epidemiological analyses evaluating incidence, prevalence
and survival, looking in particular at trends over a period of
time. Survival was addressed in 15 studies (11 focusing solely on
survival, together with another 4 in which survival data were only
part of the overall study) (Table 4).The greater part of these studies were based on data from the
U.S. (9 studies, published in the period 1993–2003). Contribu-
tions from other national registries included, in chronological
order, one from Sweden (1982), one from Canada (1996), two
from Italy (1999 and 2003), one from France (2007), one from
the U.K. (2007) and one from Germany (2008).
These studies focused mainly or secondarily on survival in
CF, the aim being to ascertain an improving trend, identify any
prognostic factors and, in some cases, attempt to provide a
predictive model of survival.
Kollberg et al. [1] compare Swedish and U.S. data, albeit
with reservations (5-year survival curves for Sweden, as
opposed to 10-year curves for the U.S.). The authors of the
Canadian study [2] acknowledge a number of limitations in
their national registry, such as the availability of clinical data
only for a 5-year period, the lack of information on pancreatic
function and the scarcity of microbiological data (only one
sputum or throat swab culture per year). They observe an
increase in median survival age for both males and females,
from 26.6 and 19.7 years respectively in the period 1970–1974
to 29.5 and 21.3 years for 1985–1989. Differences were also
noted between the East, West, Ontario and Quebec regions, with
an interesting historical evolution. Quebec had the worst
survival in the early 1970s, but showed a dramatic improvement
in the late 1980s with the introduction of the hypercaloric diet.
European analyses, based on data from Italy [3,4], France
[5], the U.K. [6] and Germany [7], also show improved survival
in CF.
For the Italian registry, a first study [3], limited by the short
period of observation, shows increased median age at death
Table 3
Publications for each of the main issues considered and each CF registry.
CF
Foundation
USA
UK
CFD
Epidemiologic
Study of Cystic
Fibrosis
(ESCF) USA
French
Registry
European
Registry
(ERCF)
German
Registry
Italian
CF
Registry
Canadian
CF
Foundation
Registry
Belgian
Registry
Swedish
Registry
Others (or several
registries at the
same time)
Total
Mortality and
survival
8 1 1 1 2 1 1 15
Incidence 1 1 1 1 1 5
Comparison
between registries
1 2 3 6
Genetics 5 1 8 1 15
Screening 5 5 10
Growth and
nutrition
8 1 1 1 2 13
Microbiology 4 2 1 1 8
Pregnancy
and fatherhood
1 1 1 2 5
Complications 4 2 3 2 2 13
Transplants 5 5
Other 9 2 6 3 20
Total 50 13 13 12 7 5 3 2 1 1 8 115
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with a difference between genders (male 18.4 years vs female
16.8 years). This trend is confirmed in another study [4],
showing that the percentage of patients reaching adulthood
more than doubled in the period 1988–2000 (from 17% toTable 4
Survival studies (order by year of publication).
Ref 1st author Year Period Registry Focus
[1] Kollberg 1982 1968–1977 Sweden Incidence and survival curv
[8] FitzSimmons 1993 1969–1990 CFF USA General epidemiology.
[2] Corey 1996 1970–1989 Canadian
CF
Foundation
Incidence, prevalence and m
(and differences between th
[13] Kosorok 1996 1989–1991 CFF USA Development of a statistica
taking into account possible
occurring before diagnosis.
[15] Singer 1997 1966–1972
versus
1994–1995
CFF USA Evaluate excess death rate f
the general population, by a
[9] Rosenfeld 1997 1988–1992 CFF USA Survival to ascertain the pre
identify potentially respons
[3] Bossi 1999 1988–1997 Italy Regional distribution of pat
basis for diagnosis, median
[10] Liou 2001 1993 CFF USA Development and validation
[11] O'Connor 2002 1982–1998 CF USA Development a case mix ad
[4] Viviani 2003 1988–2000 Italy Monitor changes in age of
[14] O'Connor 2003 1991–1998 CFF USA Association between family
[12] Kulich 2003 1985–1999 CFF USA Survival by age group.
[5] Bellis 2007 1998–2003 France Mortality and other demogr
and estimate of their total n
[6] Dodge 2007 1968–2003 UK Mortality and estimate of li
[7] Stern 2008 1995–2005 Germany Use of Registry as an instru
Comparison between centre41%), while median age at death increased from 14 to 22 years
in the same period.
In France [5] the crude death rate, which stood at 21.6‰ in
1994–1996, peaked at 23.9‰ in 1995–1997 then felt steadily to
15.8‰ in 2001–2003. Death rates by age group follow thisPatients
es 116 (1968)
200 (1977)
17,857
ortality in Canada
e four regions).
3795
l model to evaluate incidence in the USA,
underestimation because of deaths
Evidence of gender gap.
19,781
or CF patients vis-à-vis
ge group; life assurance implications.
40,491 patient-years (1966–1972)
38,180 patient-years (1994–1995)
sence of a gender gap and
ible variables.
21,047
ients, incidence, age at diagnosis,
age at death.
3617
of a 5-year survival model. 5820 development
sample
5810 validation
sample
justment model for survival studies. 30,469
CFs and diagnosis methods. Mortality data 4209
income and mortality. 23,817
31,012
aphic indicators in patients
umber.
4104
ving CF population in 2003. 8284
ment of quality management.
s with a view to improving care.
6835
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and from 79.1‰ to 27.0‰ in the 45–49 age group between
1994–1996 and 2001–2003. Over the time span examined, the
most common causes of death were cardio-respiratory, followed
by liver complications. Median survival age for 2001–2003 was
36.4 years, compared to 28.1 years for 1994–1996, while life
expectancy rose from 30.4 years (1994–1996) to 39.1 years
(2001–2003). The authors underline the possibility that a
variable part of the improved survival could be attributed to the
diagnosis of an increasing number of mild forms of the disease
(i.e. pancreatic sufficient patients). The study has the important
limit of recording only 63% of the French CF patients.
In the U.K., an extensive and detailed retrospective analysis,
complemented by demographic data from non-registry sources,
shows decreased mortality in relation to more recent birth
cohorts, estimated median survival age for those born in 2000
being 50 years [6]. The authors remark the importance of
ascertaining late-diagnosed, milder cases. They also consider it
important that criteria for diagnosis should be consistent and
that patients with CFTR-related disorders, such as isolated
obstructive azoospermia, who do not meet the diagnostic
criteria of CF and have a condition with little impact on life
expectancy, be excluded from the study. For comprehensive
epidemiologic analysis, this study also shows the importance of
combining registry data and other sources of data (pediatric and
pulmonologist consultants, death certificate authorities).
The 2008 German study [7] spans the period 1995–2005,
showing an increase from 18.5 to 23.7 years in median age at
death, while the median length of survival of the German CF
population was 37.4 years. The study also shows a correlation
of survival with nutritional status and respiratory function.
The CFF-U.S. registry is the one which has generated most
publications. One of the first reports regarding improved
survival is for the period 1969–1990, showing a progressive
increase in the number of patients in the registry (from about
8000 in 1969 to some 18,000 in 1990), in the percentage of
adult patients (from 8% to 33%) and in their survival (median
survival growing from 14 to 28 years). The article also provides
one of the first observations regarding the difference in
prognosis according to sex (median survival being 25 years
for females vs 30 years for males) [8]. This “gender gap”, to the
detriment of females, is one of the most important observations
in survival studies, being highlighted in all the U.S. data from
Fitzsimmons et al. [8] through to later studies [9–11]. However,
the analysis did not identify any statistically significant
association between the higher female mortality and any
potential demographic or clinical causative factors. Kulich et
al. [12] also report a worse prognosis for females in the age
range 2–20 years, while Kosorok [13] identifies a worse
prognosis in females and non-whites. Higher mortality for CF
patients than for the general population is reported only up to
the age of 30 years. Similar observations on the gender gap in
CF survival can be found in studies from Canada [2], Italy [3]
and the U.K. [6], but not in German patients [7].
The survival analysis allows analysis of survival time in
cohorts with different follow up. This approach is reported in a
U.S. study [12], covering the period 1985–1999, whichidentifies increased survival above all for age groups between
2 and 15 years (mortality being reduced by 60% for the 2–
5 year group, by 70% for the 6–10 year group and by 45% for
the 11–15 year group). The authors of the study found it
difficult to establish the actual survival trend for patients aged
over 16 years, and were unable to correlate trends for increased
survival with clinical data. Mortality was related to respiratory
failure, followed by liver disease, but the authors also report
post-transplant complications as a significant cause of death.
Liou's study attempts to formulate and validate survival study
models examining several variables linked to CF [10]. In clinical
practice, prognosis for morbidity and mortality depends on many
factors which coexist in the same patient and whose combined
evaluation should allow a more accurate estimate of life
expectancy. To obtain a 5-year survival model, a number of
factors were examined: age, FEV1%, gender, weight-for-age z-
score, pancreatic sufficiency, diabetes mellitus, Staphylococcus
aureus (SA) infections, Burkholderia cepacia (BC) infections,
annual frequency of acute pulmonary exacerbations. Compro-
mised respiratory function and nutritional status, female gender
(for unknown reasons, irrespective of pregnancy), BC infection
and diabetes have a negative impact on 5-year survival (in the case
of diabetes, irrespective of other covariates). Acute pulmonary
exacerbations seem to have amajor impact in terms of progression
of disease, four exacerbations per year being a negative predictive
factor with an equivalent impact to BC infection.
Another approach to the extreme heterogeneity of CF, given
the large number of variables affecting prognosis and making it
difficult to establish direct cause–effect relationships, is to
identify characteristics for case mix adjustment, evaluating
them to assess the effects, exposure or efficacy of a treatment in
the CF population [11]. O'Connor's model takes 6 variables
into account: gender, age at diagnosis, ethnic group, sodium
level in sweat, symptoms at diagnosis and genotype. Factors
associated with increased mortality were female gender, age at
diagnosis b6 months, presence of respiratory and gastrointest-
inal symptoms and meconium ileus at diagnosis, Hispanic
ethnicity, F508del homozygosis and non-F508del/non-F508del
heterozygosis, and low income. One study [14] which focuses
on income data from the U.S. registry shows that higher family
income is associated with improved CF prognosis in terms of
mortality, against the background of a system in which access to
healthcare is far from uniform. Poor nutritional status is
observed earlier in lower income groups, with retardment of
growth and more severe respiratory symptoms, nor is the gap
vis-à-vis more affluent families closed in higher age groups.
Limits in this study are that income data are presumed only on
the basis of the zip code and that there is no evaluation of
factors, related in part to economic status, such as compliance
with treatments and environmental factors (i.e. passive smoking
habits and indoor and outdoor pollution).
Despite increased survival, specific mortality by age group
in CF patients is far higher than in the general population [15].
Authors emphasize repercussions of this on life assurance
premiums, higher for CF patients than for the general population
Main findings from survival studies are summarized in
Table 4.
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Analysis of retrospective mortality studies on historical
registry-based cohorts of CF patients included large series like
those of the US-CFF. and data from other national registries
(Sweden, Canada, Italy, France, U.K., Germany). Increased
survival in CF was found, particularly for younger age groups,
with a continually improving trend despite the lack of
etiological treatment in the period analysed (1966–2005).
The most recent data show a median survival age of
36.4 years in France, based on 2003 data [5], 37.4 years in
Germany, based on 2005 data [7] and 37.4 years in the U.S.,
based on 2007 data [16]. Survival studies of cohorts with
different years of birth make it possible to estimate survival at
over 50 years for patients born after 2000 [6].
In these survival studies the probability distribution is
expressed as median length of life, indicating the age at which a
newborn of a given period has a 50% theoretical chance of
surviving. Totally different is the median age at death, which is
calculated only from dead subjects. The calculation of median
survival age may thus underestimate the median survival age of
patients now alive, since it is based on past experience. On the
other hand, selecting patients living at a given date implies a
survivor bias, since subjects within the reference population
who died before this cut-off date are excluded and this does not
allow a correct survival analysis.
The bibliographic analysis also shows a progressive increase
of the number of patients included in the registries (a findingTable 5
Main findings from survival studies.which theoretically could be correlated to increased prevalence
of the disease, increased survival and the more widespread use
of registries) and the changing distribution of patient age groups
within the registries (which can be correlated both to increased
survival and to new diagnoses in adults).
The improved survival, increased number and increased
mean age of CF patients worldwide are evident, but there are
several kinds of factors influencing these data. On the one hand,
they could be attributed to improved treatment, such as
increased attention to nutritional status, as demonstrated by
the Canadian experience [2]. On the other hand, the registries
include almost all CF patients, and the ability to identify milder
forms of disease, on the basis of the readiness of clinicians to
search for a CF diagnosis in atypical patients and the availability
of extended mutation analysis, could be an important source of
bias [5,6]. Reporting the outcome of patients with only “disease
causing” mutations or evaluating different cohorts on the basis
of the presence or absence of pancreatic insufficiency and/or the
year of birth and/or the age and mode of diagnosis (i.e.
screening versus symptoms) could overcome this issue, as was
tried by Kulich et al. [12], whose sensitivity analysis mitigate
against the impact of milder CF phenotype thus explaining
improved survival results.
In many cases the authors have suggested various negative
prognostic factors. In particular, female gender is recognized in
several studies as having a negative impact on survival [2,3,6,
8–13]. The reasons for this gender gap are not readily explained
by available data, although recent experimental data could
236 R. Buzzetti et al. / Journal of Cystic Fibrosis 8 (2009) 229–237support a “hormonal” hypothesis [17]. Mortality in CF is indeed
related to compromised respiratory function, liver complica-
tions and malnutrition (Table 5). Considering that prognosis of
CF is multifactorial and still not fully understood, the analyses
of prognostic factors are obviously not conclusive. Studies often
focus on respiratory function and nutritional parameters which
are known to change only slowly in the course of CF. While
there are some reports on the effects of family income, these are
still tentative since the methodology of assessing income levels
in relation to postal code obviously lacks fine-tuning [14].
With regards to identification of prognostic factors and the
question of why some are negative (e.g. female gender),
analyses based on registry data are often limited (there being no
assessment of exposure to environmental pollution, active and
passive smoking, physical exercise, medical therapies and
respiratory function at diagnosis). Given the complexity of the
problem, data from registries could provide sufficient informa-
tion only if data about treatment regimens, pulmonary function
tests (including infant measures), microbiology and complica-
tions will be fully available.
Correct methodology was of fundamental importance in
these studies, with survival analyses by age group or year of
birth and emphasis on avoiding bias as a result of so-called
atypical and CFTR-related forms.
Overall, the publications reviewed have a number of
strengths and weaknesses. Weaknesses are in some cases
general (e.g. incompleteness of records, lack of comparability
between different registries), in others specific to a particular
study setting. Territorial coverage is in some cases incomplete,
raising the issue of possible complementary data collection
from sources other than the national registries [6]. Strong points
are the large numbers of subjects studied (tens of thousands in
some cases) and the length of follow-up.
Intra-registry comparisons between different centres or
periods [2] can give significant results about different
therapeutic strategies or choices (i.e. to screen or not to screen),
whereas it could be more difficult to have inter-registry
comparisons because of differences in data sets, growth or
pulmonary function data references, timing of recall data, etc.
Case-mix adjustment, which is the process of correcting for
bias caused by baseline differences in patient, setting and
disease characteristics, is necessary to remove or reduce the
effects of confounding factors in studies where the subjects are
not randomly assigned to different treatments or exposures, so
that their outcomes can be compared in a standardised way [11].
It makes it possible to develop comparisons providing answers
to many questions regarding treatment effects or differences in
mortality outcomes.
There are some interesting studies intended to identify
survival models incorporating several variables [10,11]. Possi-
ble methods of adjusting for the multiple variables involved in
CF prognosis are proposed for use in comparative studies, with
a view to avoiding selection bias related to basic features of the
patient and disease. Similar models have been developed to
study the effects of lung transplantation on the survival of CF
patients [18–21]. Particularly, the study by Mayer-Hamblett
et al. [19] evaluated, in a cohort of patients similar to thatstudied by Liou et al. [10], either the best clinical predictors of
2-year mortality or the diagnostic accuracy of the proposed
model when used to guide referral for lung transplant. The
predictors in these two models differ slightly most likely
because this study analyzed predictors of 2-year rather than 5-
year mortality and chose to exclude predictors that are rare or
for which the diagnosis is not standardized. For example, Liou's
study found sex to be a significant predictor of 5-year mortality,
whereas Mayer's model did not find it to be a significant
predictor of 2-year mortality. Results of studies involving lung
transplantation will be discussed in the next articles in this
series.
A powerful method for controlling confounding factors is the
Coxmodel, which is widely employed inmedical studies and also
in some of the studies examined here [2,9,10,12]. A Coxmodel is
a statistical technique for exploring the relationship between the
survival of a patient and several explanatory variables. It provides
an estimate of survival after adjustment for several variables. It
allows us to estimate the risk of death, or other events of interest,
for individuals on the basis of their prognostic variables.
However, it should be borne in mind that each model invariably
has its basic assumption— e.g., constant risk in the case of Cox's
model, a Gaussian distribution of the dependent variable at its
various levels for the linear regression model.
In order to provide survival probabilities, some studies [5,6]
use the life tables method.
A life table for a given period of observation is calculated
from the observed number of patient-years of exposure and the
observed number of deaths at each year of age, describing for
each period (e. g. 1 year) what would happen to a “fictional
cohort” (pseudo-longitudinal analysis) of newborn infants who
experience, as they get older, the mortality conditions of the
period, assuming zero migration in a stationary population
(constant birth rate and incidence of CF, etc.). The probability of
a patient surviving to a given age is the cumulative product of
the probabilities of that patient surviving each of the years prior
to that age. A survival curve exhibits such cumulative
probabilities of survival at each age.
The predictive model of Liou [10], obtained by a “deriva-
tion” sample from which the effects of the independent variables
on survival can be assessed, was applied to a “validation”
sample, on which the model could be tried and tested.
A note of caution should be expressed regarding the risk of
lack of precision of estimated effects, as a result of trying to
account for too many factors with too few patients; in such cases
large confidence intervals are observed.
Though the disease registries play a central role in
epidemiological study of CF, for more detailed analysis of
survival and prevalence national registry data should not be
considered the only representative data of the CF population.
Data from other sources, such as health care professionals,
pediatric or pulmonologist consultants and death certificate
authorities, potentially involved in the management of CF
patients but not within national registries, must also be analysed
as in the example of one U.K. study [6].
Furthermore, it is important to specify the type of control
used: internal (different groups within the same registry) or
237R. Buzzetti et al. / Journal of Cystic Fibrosis 8 (2009) 229–237external (comparison between centres or the use of vital
statistics). Finally, losses to follow-up must be evaluated, to
relate them to chance circumstances or selection.
5. Conclusions
In conclusion, information from registries requires aware-
ness of possible incompleteness of records, quality of data in
terms of consistency and updating, and the arbitrary nature of
certain operational definitions. Registries nevertheless provide
an important boost for research in CF, provided that they are
used for consistent aims— reporting; analysis of incidence and
survival trends over a period of time, both for the disease in
general and in relation to genotype, clinical profile and
microbiological data; and evaluation of socio-economic factors.
Registries seem to provide an excellent basis for development of
hypotheses and planning of priorities for future clinical
research.
Mortality and survival studies are among the most important
products of registry-based research. On the one hand, the
studies available describe important results, like the improved
survival and the increased number and mean age of CF patients,
and are able to identify some prognostic factors influencing
survival. On the other hand, we emphasize the need for further
research to evaluate effects of treatments introduced over the
last decade (e.g., DNase, inhaled tobramycin, Pseudomonas
aeruginosa-eradicating therapy) and to monitor the efficiency
and efficacy of strategies like neonatal screening (whose effects
on long-term prognosis are still largely unknown), and
prospectively new etiological treatments of CF (gene replace-
ment therapy, correction of the genetic defect, manipulation of
ion transport).
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